These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31686894)

  • 41. Arterial ammonia levels in cirrhosis are determined by systemic and hepatic hemodynamics, and by organ function: a quantitative modelling study.
    Noiret L; Baigent S; Jalan R
    Liver Int; 2014 Jul; 34(6):e45-55. PubMed ID: 24134128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
    Paik YH; Lee KS; Han KH; Song KH; Kim MH; Moon BS; Ahn SH; Lee SJ; Park HJ; Lee DK; Chon CY; Lee SI; Moon YM
    Yonsei Med J; 2005 Jun; 46(3):399-407. PubMed ID: 15988813
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Splanchnic and leg exchange of amino acids and ammonia in acute liver failure.
    Clemmesen JO; Kondrup J; Ott P
    Gastroenterology; 2000 Jun; 118(6):1131-9. PubMed ID: 10833488
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
    Blanco Vela CI; Poo Ramírez JL
    Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severe hyperammonaemia in adults not explained by liver disease.
    Walker V
    Ann Clin Biochem; 2012 May; 49(Pt 3):214-28. PubMed ID: 22349554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatocyte heterogeneity in the metabolism of amino acids and ammonia.
    Häussinger D; Lamers WH; Moorman AF
    Enzyme; 1992; 46(1-3):72-93. PubMed ID: 1289083
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ammonia-lowering strategies for the treatment of hepatic encephalopathy.
    Rose CF
    Clin Pharmacol Ther; 2012 Sep; 92(3):321-31. PubMed ID: 22871998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
    Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rifaximin in the treatment of chronic hepatic encephalopathy.
    Puxeddu A; Quartini M; Massimetti A; Ferrieri A
    Curr Med Res Opin; 1995; 13(5):274-81. PubMed ID: 7555036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative study of basal arterial ammonemia and of orally-induced hyperammonemia in chronic portal systemic encephalopathy, treated with neomycin, lactulose, and an association of neomycin and lactulose.
    Pirotte J; Guffens JM; Devos J
    Digestion; 1974; 10(6):435-44. PubMed ID: 4448315
    [No Abstract]   [Full Text] [Related]  

  • 51. Metabolic adaptation of the kidney to hyperammonemia during chronic liver insufficiency in the rat.
    Dejong CH; Deutz NE; Soeters PB
    Hepatology; 1993 Oct; 18(4):890-902. PubMed ID: 8406365
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ammonia: key factor in the pathogenesis of hepatic encephalopathy.
    Butterworth RF; Giguère JF; Michaud J; Lavoie J; Layrargues GP
    Neurochem Pathol; 1987; 6(1-2):1-12. PubMed ID: 3306479
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of glutamine in adaptations in nitrogen metabolism during fasting.
    Cersosimo E; Williams PE; Radosevich PM; Hoxworth BT; Lacy WW; Abumrad NN
    Am J Physiol; 1986 Jun; 250(6 Pt 1):E622-8. PubMed ID: 3521309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation of interorganal glutamine flow in metabolic acidosis.
    Welbourne TC; Phromphetcharat V; Givens G; Joshi S
    Am J Physiol; 1986 Apr; 250(4 Pt 1):E457-63. PubMed ID: 3963187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is increased ammonia liberation after bleeding in the digestive tract the consequence of complete absence of isoleucine in hemoglobin? A study in pigs.
    van Berlo CL; van de Bogaard AE; van der Heijden MA; van Eijk HM; Janssen MA; Bost MC; Soeters PB
    Hepatology; 1989 Sep; 10(3):315-23. PubMed ID: 2788117
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
    Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of chronic uremia on portal and systemic ammonemia in normal and portal-strictured rats.
    Imler M; Schlienger JL
    J Lab Clin Med; 1979 Dec; 94(6):872-8. PubMed ID: 501211
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Control of acute, chronic, and constitutive hyperammonemia by wild-type and genetically engineered Lactobacillus plantarum in rodents.
    Nicaise C; Prozzi D; Viaene E; Moreno C; Gustot T; Quertinmont E; Demetter P; Suain V; Goffin P; Devière J; Hols P
    Hepatology; 2008 Oct; 48(4):1184-92. PubMed ID: 18697211
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.